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Abstract: Background: Hypertension remains the largest attributable risk factor of cardiovascular
disease (CVD), and a reduction of cardiovascular events is linked to diminished elevated blood
pressure (BP) values. High alcohol intake is a common cause of hypertension, but some studies
have suggested that moderate wine consumption may reduce BP and increase plasma nitric oxide
(NO) due to its polyphenol content. Objective: The aim of the present study was to compare the
effects of Andalusian aged white wine (AWW) under a veil of flor, an alcoholic beverage with a
moderate polyphenol content, with those of gin, an alcoholic beverage without polyphenols, on BP
and plasma NO in men at high cardiovascular risk. Methods: This study was designed as an open,
randomized crossover-controlled trial in which 38 high-risk male volunteers, aged 55 to 80, received
30 g of ethanol daily in the form of AWW or gin. This was carried out over the course of three weeks,
after a two-week washout period. At baseline and after each intervention period, BP, anthropometric
parameters, and plasma NO were measured; food intake was also recorded, and physical activity was
monitored. Results: Compared to gin, AWW significantly reduced systolic and diastolic BP (p ≤ 0.033;
both) and increased plasma NO levels (p = 0.013). Additionally, changes in BP values observed after
AWW significantly correlated with increases in plasma NO. No changes in food intake, physical
activity, body weight, or waist were observed between the two intervention periods. Conclusions:
Moderate daily consumption of AWW may be useful to reduce elevated BP due to an increase of NO
synthesis. This effect could be attributed to grape-derived compounds in AWW, such as polyphenols,
which are not present in gin.
Keywords: wine; Andalusian aged white wine; blood pressure; nitric oxide; cardiovascular
risk; polyphenols
1. Introduction
Elevated blood pressure (BP) represents a public health problem worldwide and is considered
one of the major underlying causes of morbidity and mortality in cardiovascular disease (CVD) [1,2].
Epidemiological evidence suggests that moderate alcohol consumption may reduce CVD [3] and that
alcoholic beverages may exert at least part of these beneficial effects by lowering BP [4].
Although hypertension is a multifactorial disease, there is growing scientific evidence showing
that dietary nitrite and nitrate intake can affect BP values and even CVD [5]. Population studies
have observed a negative association between dietary intake of nitrites and nitrates and the risk of
hypertension [4–9]. This association has also been reported in short-term clinical trials evaluating the
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effects of nitrate-rich foods, such as apples and spinach, in hypertensive patients [7,10,11]. Similarly,
interventional studies performed in experimental animals and humans have evaluated the effects
of red wine extract, alcohol, and red wine on BP and reported an association between the lowering
effect of red wine on BP and the increasing plasma concentrations of nitric oxide (NO) observed.
The reduction of BP is due to increased vasorelaxation induced by enhancing NO synthase activity
and NO production [12]. In another clinical trial, the hypotensive effects of de-alcoholized red wine
were greater than those observed with regular red wine, attributing this effect to the polyphenols
and other bioactive compounds contained in red wine [13]. Among other proposed mechanisms of
plasma NO increases include improvements in endothelial function and vascular relaxation, while
other mechanisms proposed for the increase in plasma NO include improvements in endothelial
function and vascular relaxation [5].
Since no previous study has evaluated the effects of white wines on BP and plasma NO
concentrations, this clinical trial was aimed at analyzing the short-term effects (21 days) of a sherry
variety of Andalusian white wine (AWW), also called “AWW aged under a veil of flor”, on BP
parameters and plasma NO concentrations in men at high cardiovascular risk.
2. Materials and Methods
2.1. Participants
Participants were men aged between 55 to 80 years with no previous history of documented
CVD, who were screened from October 2012 to February 2014 in a primary care center associated with
the Hospital Clínic of Barcelona (Spain). All participants were low-to-moderate alcohol consumers
(around 30 g/ethanol/day) and had diabetes mellitus or 3 or more of the following CVD risk factors:
active smoking, hypertension, plasma LDL cholesterol of >4.13 mmol/L (>160 mg/dL), plasma HDL
cholesterol of <0.905 mmol/L (<35 mg/dL), overweight, or obesity (body mass index [BMI] of >25 kg/m2),
and/or a family history of premature coronary heart disease (CHD). The exclusion criteria included
documented CHD, stroke or peripheral vascular disease, human immunodeficiency virus infection,
alcoholic liver disease, malnutrition, and neoplastic or acute infectious diseases. None of the study
subjects were consumers of vitamin supplements or anti-inflammatory drugs (steroids, non-steroidal
anti-inflammatory agents, or aspirin).
The Institutional Review Board of the Hospital Clinic approved the study protocol, and all
participants gave written consent to participate in the study. Furthermore, this study was registered in
the International Standard Randomized Controlled Trial Number (ISRCTN) register with the number
01319643 (www.controlled-trials.com).
2.2. Study Design
The study was an open, randomized, controlled, crossover trial with four intervention periods.
Each intervention period was comprised of three weeks, with a 2-week washout period between
the two interventions. During the washout period, the volunteers were asked not to consume any
alcoholic beverages. Moreover, the design, methodology, and eligibility criteria for this study have
been published previously [14].
After signing the informed consent form, volunteers were randomized using a computer-generated
random-number table into one of two interventions in a crossover design; one included the
administration of 92 mL of gin (30 g ethanol/day) and the other included the same amount of
ethanol as AWW (255 mL total phenol: 927.79 Eq. gallic acid/day [EGA/day]), with an ethanol content
of 13%. Both groups followed a common background diet. Furthermore, a washout period was
included between interventions.
The phenolic profile of the AWW and gin used in the trial was determined by SPE-LC-ESI-MS/MS
and is shown in Table 1. Interestingly, the total polyphenol compounds of AWW used in this study
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were nearly 3-fold the amount of polyphenols detected in a common white wine (321 milli Equivalent
gallic acid (mEqGA)/L) [14]. No detectable phenolic compounds were observed in gin.
Table 1. Phenolic composition of the aged white wine studied.
AWW
Total Phenols (mEqGA/L) 927.8
Gallic acid (mg/L) 6.0
Protocatechuic acid (mg/L) 5.6
4-Hydroxybenzoic acid (mg/L) 0.3
Vanillic acid (mg/L) 0.7
Syringic acid (mg/L) 1.5
Caffeic (mg/L) 1.0
Caffeoyl tartaric acid(mg/L) 17.5
Ferulic acid (mg/L) 0.2
p-Coumaric acid (mg/L) 0.2




Procyanidin dimer B1 (mg/L) 20.0
Procyanidin dimer B2 (mg/L) 7.2
Procyanidin dimer B3 (mg/L) 14.7
Procyanidin dimer B4 (mg/L) 3.5
Flavonols
Quercetin (mg/L) 0.1
Quercetin 3-O-arabinoside (mg/L) -







AWW: Aged White Wine; GAE: Gallic Acid Equivalents.
2.3. Diet and Exercise Monitoring
The participants were asked to maintain their usual dietary habits and physical activity. They were
also asked to abstain from alcoholic beverages other than those provided by the investigative team.
Participants were not blinded to the type of drink ingested. Furthermore, the participants’ diet was
closely monitored, especially in relation to foods rich in antioxidants, such as fruit, vegetables, tea,
and coffee, to ensure that the individual diets had similar antioxidant content throughout the study.
At baseline and after each intervention period, diet and physical activity were monitored.
A validated 3-day (2 work days and 1 weekend day) food recall questionnaire was used to evaluate
the diet followed by each participant during each intervention period [15]. These questionnaires were
also used to assess adherence to the study. The dietary information recorded was converted into
nutrient data using the Food Processor Nutrition and Fitness Software (ESHA Research, Salem OR,
2012 10.10.0), which was adapted to local foods. Furthermore, the Minnesota Leisure Time Physical
Activity Questionnaire was administered to monitor the physical activity of the participants throughout
the study [16]. Empty AWW and gin bottles of the participants were counted to ensure compliance.
At the end of each intervention period, a checklist of clinical symptoms such as bloating, altered
bowel habit, or dizziness, as well as other possible symptoms, was administered to the participants to
identify possible side effects related to the interventions.
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2.4. Clinical and Laboratory Measurements
At baseline and after each intervention, a trained nurse measured the BP and heart rate in triplicate
at 5 min intervals in the non-dominant arm after 15 min of resting in a seated position. The BP was
measured with a validated semiautomatic oscillometer (Omron 705 CP; Omrom Matsuasaka Co Ltd.,
Matsuasaka City, Japan). The mean of the second and the third measurements was used for statistical
analysis. In addition, anthropometric measurements including height, body weight, waist, and hip
perimeters were made using standardized methods [17].
The last day of the run-in period (at baseline) and after each intervention period (AWW or gin)
fasting blood, serum, EDTA-plasma, and urine samples were collected and immediately centrifuged
and stored at −80 ◦C until assayed. The participants had fasted 12 h prior to blood analyses. Additional
serum analytes including plasma aspartate aminotransferases (AST), alanine transaminase (ALT),
gamma glutamyltranspeptidase (GGT), albumin, cholesterol, prothrombin time, folic acid, and vitamin
B12 were measured to determine the possible adverse effects of ethanol intake. For the measurement of
nitric oxide (NO), the release of NO2– and NO3, the stable breakdown products of NO in plasma, were
determined by a chemiluminescence detector in an NO analyzer (Sievers Instruments, Boulder, CO,
USA) [13]. Finally, the concentration of tartaric acid in 24 h urine was also measured before and after
each intervention to assess compliance with the intervention assigned [18].
2.5. Statistical Analysis
The ENE 3.0 statistical program (GlaxoSmithKline, Brentford, United Kingdom) was used to
determine sample size. For a cross-over design and assuming a maximum loss of 10% of participants,
to detect a mean difference of 4.1 µmol/L of NO with a conservative standard deviation (SD) of 6.0,
at least 22 subjects are needed for the study (α risk = 0.05, power = 0.9).
The statistical analyses were carried out using the SPSS statistical analysis system v20.0 (SPSS,
Chicago, IL, USA). Descriptive statistics (mean ± SD or n [%]) were used to describe the baseline
characteristics of the participants and the outcome variables. The paired two-tailed t-test was used
to compare changes in outcome variables in response to each intervention period and carryover
effects for the outcome variables observed before the AWW and gin periods. We also compared the
differences in the parameters obtained between the groups starting with AWW and then with gin.
The paired two-tailed t-test was also used to compare differences in the effects of each intervention.
Pearson’s correlation analysis was used to quantify relationships between changes in blood pressure
and plasma NO concentrations. The effects of each intervention, as well as differences between the two
interventions, are expressed as mean changes (95% confidence interval, CI).
3. Results
3.1. Characteristics of the Participants and Assessment of Side Effects
A total of 47 potential candidates were pre-screened for eligibility. Figure 1 shows the study
flowchart. Of the 47 candidates, two did not meet the inclusion criteria and four refused to participate;
therefore, 41 were randomized to two sequences of interventions: (1) AWW and gin (n = 21); and (2)
Gin and AWW (n = 19). However, three participants included in the first sequence dropped-out; thus,
38 completed the study and were included in the analysis. Table 2 shows the baseline characteristics
of the participants studied. Most were overweight or obese (88%), more than half had dyslipemia
(54%), nearly three-quarters had hypertension (73%), and a fifth have type-2 diabetes (21%), while 13%
were smokers.
Serum folic acid, vitamin B12, albumin, creatinine, AST, ALT, and GGT concentrations remained
within the normal range throughout the study. No subjects reported any adverse effects during
the interventions.
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Figure 1. Flowchart.
Table 2. Baseline characteristics of the 38 study subjects.
Mean ± SD or %
Age (years) 68.7 ± 5.4 a
Height (cm) 168.9 ± 6.2
Body weight (kg) 82 ± 11.1
BMI (kg/m2) 28.7 ± 3.2
BMI ≥ 25 kg/m2 [n (%)] 35 (92) a
Waist circumference (cm) 105 ± 7
Hypertension [n (%)] 27 (71)
Type 2 diabetes mellitus [n (%)] 8 (23)
Dyslipidemia [n (%)] 20 (53)
Current smokers [n (%)] 5 (13)
Sedentariness [n (%)] 4 (11)
Family history of premature CHD [n (%)] 4 (11)
Systolic blood pressure (mmHg) 144.2 ± 16.2
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Table 2. Cont.
Mean ± SD or %
Diastolic blood pressure (mmHg) 76.9 ± 9.7
Heart rate (beats/min) 65.3 ± 9.2
Diuretics [n (%)] 10 (26)
Statins [n (%)] 15 (39)
Fibrates [n (%)] 13 (34)
ACE inhibitors [n (%)] 19 (50)
Oral hypoglycemic drugs [n (%)] 14 (37)
Aspirin or antiplatelet drugs [n (%)] 9 (24)
Others [n (%)] 17 (45)
Glucose (mg/dL) 111.3 ± 23.3
Total cholesterol (mg/dL) 170.8 ± 38.5
LDL-cholesterol (mg/dL) 103.9 ± 36.1
HDL-cholesterol (mg/dL) 44.8 ± 14.4
Triglycerides (mg/dL) 105.5 ± 54.5
ALT (IU/L) 25.5 ± 11.6
AST (IU/L) 25.3 ± 11.7
GGT (IU/L) 21.4 ± 13.8
Folic acid (serum) (ng/mL) 8.9 ± 2.9
Vitamin B12 (pg/mL) 399.5 ± 175.4
Apo A1 (mg/dL) 113.7 ± 18.9
Apo B (mg/dL) 79.3 ± 19.2
Lipoprotein (a) (mg/dL) 37.1 ± 54.1
SD: standard deviation; BMI: body mass index; CAD: coronary artery disease; ACE: angiotensin-converting enzyme;
LDL: low-density lipoprotein; HDL: high-density lipoprotein; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; GGT: gamma glutamyl transpeptidase; ApoA1: apolipoprotein A1; ApoB: apolipoprotein B;
a Values are mean ± SD or n (%).
3.2. Intervention, Diet, and Physical Activity Monitoring
In a crossover design, all participants underwent both interventions—30 g of ethanol as AWW
or gin in a random sequence. Twenty-one participants started with AWW and the other 19 with
gin. The number of empty bottles returned after each intervention period, and the results of the
self-reported 3-day questionnaire of food consumption, showed good adherence to the study protocol.
Tartaric acid was measured as a biomarker of wine consumption and was also used as a measurement
of intervention compliance [18]. This measurement was made in 24 h urine samples that were collected
on the last day of the run-in period and after each intervention. Results showed a significant increase in
the 24 h excretion of tartaric acid after AWW consumption (from 14.09 ± 31.80 to 63.79 ± 39.73 µg/mL,
p < 0.001).
No changes in the usual dietary habits or physical activity were reported throughout the study in
the participants’ dietary and Minnesota reports (Table 3). In addition, none of the participants reported
changes in the medications used.
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Table 3. Values of the mean nutrients and physical activity before and after the 3-week aged white wine (AWW) and gin interventions.
Before AWW
Mean ± SD +
After AWW




Mean ± SD +
After Gin
Mean ± SD +
Mean Differences
(95% CI) ‡ p-Value
Physical activity
(METS/week) 6560 ± 6333 6686 ± 6531 125.94 (−733.80 to 985.70) 5783 ± 4624 6477 ± 6379 694 (−1294to 2682) 0.481
Energy (Kcal) 1753 ± 264 1965 ± 353 212.03 (83.95 to 340.10) * 1730 ± 301 1972 ± 397 242.02 (−90.50 to 393.54) * 0.003
Protein (g) 82.35 ± 15,63 86.07 ± 14.61 3.71 (−2.75 to 10.18) 84.15 ± 16.53 83.61 ± 18.01 −0.53 (−8.94 to 7.86) 0.896
Carbohydrates (g) 187.72 ± 39.05 196.64 ± 50.72 8.92 (−6.63 to 24.48) 187.81 ± 47.92 196.53 ± 54.37 8.71 (−14.96 to 32.39) 0.456
Dietary fiber 17.19 ± 5.10 17.67 ± 6.96 0.48 (−1.81 to 2.78) 17.28 ± 6.25 16.90 ± 7.61 −0.38 (−3.24 to 2.47) 0.785
Total fat (g) 78.41 ± 17.82 73.01 ± 16.17 −5.41 (−12.54 to 1.72) 76.55 ± 18.28 73.30 ± 18.22 −3.25 (−11.71 to 5.20) 0.436
Cholesterol (mg) 278.42 ± 63.70 281.69 ± 106.31 3.26 (−44.32 to 50.86) 281.37 ± 72.40 272.48 ± 85.56 −8.89 (−54.70 to 36.92) 0.693
Polyphenols (mg) 1192 ± 374 1428.41 ± 641.62 236.30 (28.80 to 443.80) * 1281 ± 588 1294 ± 608 12.99 (−282.69 to 308.68) 0.929
Alcohol (g) 0.00 ± 0.00 26.17 ± 0.32 26.17 ( 26.04 to 26.30) * 0.00 ± 0.00 29.26 ± 1.88 29.26 (28.49 to 30.02) * <0.001
Results are expressed as + mean ± standard deviation (SD) (n = 38) and ‡ mean differences (95% confidence interval [CI]) between before and after each intervention. Before each
intervention is the value of the previous intervention or the baseline in the first intervention. METS: metabolic equivalent. * p: Significant differences (p < 0.05) between before and after the
intervention (intra-group changes). p-Value: Statistical differences between group changes.
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3.3. Changes in Cardiovascular Risk Factors after 3 Weeks of Intervention
After the 3-week intervention with AWW, systolic and diastolic BP showed a mean reduction
of −4.91 mmHg (95% CI: −9.41 to −0.42; p = 0.033) and −2.90 mmHg (CI: −5.50 to −0.29; p = 0.030),
respectively. A comparison between groups showed significant reductions in systolic BP and diastolic
BP after AWW intake compared to gin (p < 0.040; both) (Table 4). Following the AWW intervention,
plasma NO concentrations significantly increased from baseline to 21 days after the intervention
(p = 0.013); however, no significant changes were observed in a comparison between groups (p > 0.05).
In the subgroup analyses, we did not find differences in the effects of AWW and gin on
BP and plasma NO concentrations in the different subgroups analyzed; that is, in smoker vs.
non-smoker, diabetic vs. non-diabetic, hypertensive vs. non-hypertensive, and dyslipidemic vs.
non-dyslipidemic subjects.
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Table 4. Mean biomarker values before and after the 3-week aged white wine and gin interventions.
BIOMARKERS BEFORE WINEMean ± SD +
AFTER WINE




Mean ± SD +
AFTER GIN
Mean ± SD +
Mean differences
(95% Cl) ‡ p p-Value
Systolic BP (mmHg) 141.78 ± 14.94 136.87 ± 13.17 −4.91 (−9.41 to −0.418) * 0.033 137.43 ± 15.87 139.55 ± 17.51 2.12 (−2.31 to 6.56) 0.338 0.039
Diastolic BP (mmHg) 76.34 ± 9.29 73.44 ± 10.50 −2.90 (−5.50 to −0.295) * 0.030 72.83 ± 11.87 73.44 ± 910.87 0.61 (−1.64 to 2.86) 0.585 0.039
Heart rate (lpm) 65.15 ± 8.64 64.66 ± 9.69 −0.49 (−3.52 to 2.53) 0.743 65.76 ± 10.26 65.91 ± 9.45 0.15 (−3.26 to 3.57) 0.928 0.538
Weight (Kg) 81.77 ± 10.94 82.06 ± 10.64 0.28 (−0.21 to 0.78) 0.248 82.00 ± 10.86 82.29 ± 10.66 0.29 (−0.76 to 0.66) 0.116 0.496
Body mass index
(Kg/m2) 28.73 ± 3.12 28.84 ± 3.04 0.11 (−0.07 to 0.30) 0.222 27.91 ± 5.15 28.73 ± 3.02 0.81 (−0.84 to 2.48) 0.325 0.285
Waist circumference
(cm) 103.37 ± 7.61 102.98 ± 8.30 −0.38 (−1.70 to 0.92) 0.551 102.79 ± 8.06 102.95 ± 7.39 0.16 (−0.56 to 0.90) 0.648 0.484
NOx serum (µmol/L) 28.50 ± 12.62 56.37 ± 62.98 27.86 (−6.86 to 62.59) 0.013 27.48 ± 16.79 39.31 ± 43.97 11.83 (−6.63 to 6.25) 0.272 0.237
Results are expressed as + mean ± standard deviation (SD) (n = 38) and ‡ mean differences (95% confidence interval [CI]) between before and after each intervention. Before each
intervention is the value of the previous intervention or the baseline in the first intervention. METS: metabolic equivalent. * p: Significant differences (p < 0.05) between before and after the
intervention (intra-group changes). p-Value: Statistical differences between-group changes.
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4. Discussion
After 21 days of intervention with AWW and gin, in a crossover study on high cardiovascular risk
subjects, only AWW decreased systolic and diastolic BP and increased the plasma NO concentrations.
This suggests that the hypotensive effects of AWW should be attributed to non-alcohol compounds of
this type of wine, which may induce vasodilatation due to increases in plasma NO concentrations.
In this cross-over study, men with high cardiovascular risk followed two 3-week interventions with
AWW and gin with two 15-day washout periods before each intervention. When comparing the results
of AWW and gin intake, systolic and diastolic BP decreased and plasma NO concentrations increased
only after the AWW intervention, suggesting that the hypotensive effects of AWW might be attributed
to the non-alcohol compounds of this type of wine, which may induce vasodilatation due to an increase
in plasma NO concentrations.
For many years, NO has been considered an attractive therapeutic target for the cardiovascular
system. Indeed, this interest stems from various lines of research showing that increased NO
concentrations lead to vasodilatation and reduced BP, as well as improving arterial stiffness after
dietary nitrate consumption [7,10,19]. Currently, a large body of scientific evidence supports the role
of NO as the key regulator of vascular homeostasis and as a natural vasodilator, because NO reduces
the vascular oxidative stress and inflammation associated with arterial aging, making it a potential
therapeutic option in CVD [20–24].
In fact, systemic inflammation and oxidative stress are the pathophysiological bases of
atherosclerosis and cardiovascular risk factors [25]. We have previously reported [14] that moderate
consumption of AWW significantly improves systolic and diastolic BP, as well as HDL-cholesterol
and apolipoprotein A1 concentrations. While changes observed in HDL and apolipoprotein A1
concentrations might be attributed to alcoholic fraction (ethanol), the BP-lowering effects also observed
in the study could be attributed to polyphenols (such as resveratrol or others) or other minor
components of AWW and not to alcohol. Additionally, we also reported a reduction in the expression
of leucocyte adhesion molecules, circulating endothelial progenitor cells, and inflammatory cytokines
and chemokines related to atherosclerosis after consumption of AWW. Since these effects were not
observed after gin intervention, we attributed them mainly to polyphenols in AWW. In this manuscript,
we also underlined that no side effects were observed in both intervention arms, including in liver and
kidney function tests [14].
Other studies have examined the relationship between hypertension and oxidative stress in
experimental animals [26] and hypertensive subjects [27,28]. However, the results of these studies
concluded that treatment with antioxidants is ineffective in hypertension, suggesting that oxidative
stress is an effect (a consequence) rather than the cause of essential hypertension [26].
Heavy alcohol intake increases the risk of hypertension in a dose-dependent manner. However,
to date, the beneficial effects observed between light or moderate alcohol consumption and hypertension
is controversial because of the confusing trends and results observed. Indeed, while some studies have
reported a linear relationship between alcohol consumption and its benefits, others did not find this
linearity or even show a J-shaped association [29,30]. In a recent meta-analysis [31] including a total of
16 prospective studies (33,904 men and 193,752 women), it was found that the risk of hypertension in
men not only increased with heavy alcohol consumption (31 to 40 g/day) but also with low (<10 g/day)
and moderate (11 to 20 g/day) alcohol consumption. On the other hand, women showed a J-shaped
relationship between alcohol consumption and hypertension. By contrast, another meta-analysis and
systemic review based on 20 cohort studies (125,907 men, 235,347 women, and 90,160 incident cases of
hypertension) found no evidence for a protective effect of alcohol consumption on hypertension in
women [32]. In addition, Taylor et al. [33] concluded that the risk of hypertension is dose-dependent
with alcohol consumption, but this dose-response relationship starts after an apparent threshold
effect at two standard drinks (24 g pure alcohol per day). With lower doses, there was an apparent
lowering effect on BP [34]. According to the results obtained in the current study and another by
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Chiva-Blanch et al. [13], the final effect of an alcoholic beverage on BP depends on the alcohol strength
of the beverage and the amount of polyphenols that it contains.
Additionally, numerous studies on the effects of polyphenols [35,36] have shown reductions in
inducible nitric oxide synthase (iNOS) expression, which is considered to be an anti-inflammatory
effect of polyphenols [36] and activation of endothelial nitric oxide synthase (eNOS), which has
positive effects on BP [37]. Several in vitro animal and experimental studies have demonstrated that
moderate consumption of wine, mainly red wine, leads to lower BP values and the enhancement of
endothelial nitric oxide production [38]. Nevertheless, although it has been reported that wine phenolic
compounds may exert their cardioprotective effect by lowering endothelial dysfunction and increasing
NO production and its availability [39,40], scientific evidence of the effects of wine polyphenols on BP
in humans remains inconsistent [41–43]. In a double-blind, placebo-controlled three-period crossover
trial [44], intake of red wine polyphenols for four weeks did not reduce BP in subjects with high-normal
BP or grade one hypertension. Similar results were found in another study performed in healthy young
women [45]. Contrarily, Sivaprakasapillai et al. [46] randomized participants with metabolic syndrome
into three parallel groups to consume a placebo, 150 mg grape seed extract/d, or 300 mg grape seed
extract/d during a 4-week treatment period. Both systolic and diastolic BP decreased after treatment
with the grape seed extracts compared with the placebo. Moreover, our results showed significant
reductions in BP after moderate consumption of AWW in subjects at high risk of CVD, who most
likely had endothelial dysfunction. The mechanism associated with a reduction of BP might be due
to the intake of the phenolic compounds (resveratrol and probably others) present in AWW. These
polyphenols would increase eNOS expression, improving endothelial dysfunction, and reducing BP.
Some studies have also shown that high doses of resveratrol (≥150 mg/d) reduce systolic BP [47].
On the other hand, Huang et al. [3] reported a significant increase in plasma NO concentrations in
healthy participants who had consumed 100 mL of red wine daily for three weeks, though no changes
were observed in BP values when volunteers consumed vodka or beer with an equivalent amount of
alcohol. Barona et al. [48] also demonstrated that compared with a placebo, the daily consumption
of grape extract for 30 days significantly improved vascular endothelial function and biomarkers of
metabolic syndrome by increasing flow-mediated vasodilation response and lowering systolic BP.
As expected, the participants maintained their usual body weight, diet, and physical activity throughout
the whole study. In addition, the consumption of a grape preparation with standardized polyphenol
content led to an improvement in vascular endothelial dysfunction, increasing NO bioavailability in
volunteers, aged 30–70 years, with metabolic syndrome [48]. As in the case of BP, the plasma levels of
NO in our study also improved following the AWW intervention, probably by polyphenols inducing
iNOS production as previously shown in some experimental studies [49]. Chiva-blanch et al. [13]
confirmed this hypothesis in their study, showing that de-alcoholized red wine polyphenols decreased
BP while increasing NO production of iNOS in healthy humans.
This study has some limitations. On the one hand, we did not identify the polyphenol(s)
responsible for the effects observed. In addition, endothelial function was not measured. Furthermore,
it would be interesting to also analyze oxidative stress markers such as superoxide dismutase (SOD),
glutathione peroxidase (GPx), or NADPH oxidase to confirm the results observed in relation BP or
NO levels. Finally, on the other hand, a 3-week intervention may not represent the potential effects of
long-term consumption.
5. Conclusions
This feeding trial suggests that moderate consumption of AWW has beneficial effects on the
cardiovascular system by increasing plasma NO, which may contribute to decreasing the risk of
developing hypertension and, consequently, diminishing cardiovascular risk.
Nutrients 2019, 11, 1266 12 of 14
Author Contributions: Conceptualization, design, recruitment, evaluation of the participants, statistical analyses,
and writing the manuscript: I.R. and R.E.; Recruitment and revision of the manuscript: I.R., R.E., and R.C.;
Analyses and revision of the manuscript: I.R., R.C., and R.E.; Critical revision of the manuscript: I.R., M.R.-C.,
R.C., and R.E. All authors approved the final version of the manuscript.
Funding: This work was partially supported by 11/351 Fundación Centro Tecnológico Andaluz de Diseño
(SURGENIA), Spain.
Acknowledgments: E. Corbella for statistical support.
Conflicts of Interest: R.C. reports serving on the board of and receiving lecture fees from the Research Foundation
on Wine and Nutrition (FIVIN). R.E. reports serving on the board of and receiving lecture fees from the Research
Foundation on Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and
the European Foundation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España and
Sanofi-Aventis; and receiving grant support through his institution from Novartis. No other potential conflicts of
interest relevant to this article are reported.
References
1. Weiner, D.E.; Tighiouart, H.; Amin, M.G.; Stark, P.C.; MacLeod, B.; Griffith, J.L.; Salem, D.N.; Levey, A.S.;
Sarnak, M.J. Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality:
A Pooled Analysis of Community-Based Studies. J. Am. Soc. Nephrol. 2004, 15, 1307–1315. [CrossRef]
[PubMed]
2. Lackland, D.T.; Weber, M.A. Global burden of cardiovascular disease and stroke: Hypertension at the core.
Can. J. Cardiol. 2015, 31, 569–571. [CrossRef]
3. Huang, P.H.; Chen, Y.H.; Tsai, H.Y.; Chen, J.S.; Wu, T.C.; Lin, F.Y.; Sata, M.; Chen, J.W.; Lin, S.J. Intake of red
wine increases the number and functional capacity of circulating endothelialprogenitor cells by enhancing
nitric oxide bioavailability. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 869–877. [CrossRef] [PubMed]
4. Krenz, M.; Korthuis, R.J. Moderate ethanol ingestion and cardiovascular protection: From epidemiologic
associations to cellular mechanisms. J. Mol. Cell. Cardiol. 2012, 52, 93–104. [CrossRef]
5. Machha, A.; Schechter, A.N. Dietary nitrite and nitrate: A review of potential mechanisms of cardiovascular
benefits. Eur. J. Nutr. 2011, 50, 293–303. [CrossRef] [PubMed]
6. Bahadoran, Z.; Mirmiran, P.; Ghasemi, A.; Carlström, M.; Azizi, F.; Hadaegh, F. Association between Dietary
Intakes of Nitrate and Nitrite and the Risk of Hypertension and Chronic Kidney Disease: Tehran Lipid and
Glucose Study. Nutrients 2016, 8, 811. [CrossRef]
7. Ramms, B.; Gordts, P.L. Dietary nitrate struggles in atherosclerosis. Atherosclerosis 2016, 245, 71–73. [CrossRef]
8. Habermeyer, M.; Roth, A.; Guth, S.; Diel, P.; Engel, K.H.; Epe, B.; Fürst, P.; Heinz, V.; Humpf, H.U.; Joost, H.G.;
et al. Nitrate and nitrite in the diet: How to assess their benefit and risk for human health. Mol. Nutr.
Food Res. 2015, 59, 106–128. [CrossRef]
9. Ashworth, A.; Bescos, R. Dietary nitrate and blood pressure: Evolution of a new nutrient? Nutr. Res. Rev.
2017, 17, 1–12. [CrossRef]
10. Bondonno, C.P.; Yang, X.; Croft, K.D.; Considine, M.J.; Ward, N.C.; Rich, L.; Puddey, I.B.; Swinny, E.;
Mubarak, A.; Hodgson, J.M. Flavonoid-rich apples and nitrate-rich spinach augment nitric oxide status
and improve endothelial function in healthy men and women: A randomized controlled trial. Free Radic.
Biol. Med. 2012, 52, 95–102. [CrossRef]
11. Kapil, V.; Khambata, R.S.; Robertson, A.; Caulfield, M.J.; Ahluwalia, A. Dietary nitrate provides sustained
blood pressure lowering in hypertensive patients: A randomized, phase 2, double-blind, placebo-controlled
study. Hypertension 2015, 65, 320–327. [CrossRef]
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